Arrowhead Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 2.38
Dividend & YieldN/A$ (N/A)
Beta 1.41
Market capitalization 3.17B
Operating cash flow -91.58M
ESG Scores unknown

Company description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Change To Liabilities -6.54M 87.65M -64.33M 225.89M
Total Cashflows From Investing Activities -7.43M -47.75M -240.78M -141.68M
Net Borrowings -208.51k -2.42M
Total Cash From Financing Activities 59.95M 66.38M 257.95M 11.3M
Change To Operating Activities 921.38k -155k 3.83M 10.39M
Issuance Of Stock 60.22M 68.8M 257.95M 11.3M
Net Income -54.45M 67.97M -84.55M -140.85M
Change In Cash 5.29M 191.67M -78.22M 40.85M
Effect Of Exchange Rate
Total Cash From Operating Activities -47.22M 173.03M -95.39M 171.22M
Depreciation 4.7M 4.44M 5.94M 8.27M
Change To Account Receivables -259.58k -334k -184k -9.41M
Other Cashflows From Financing Activities
Change To Netincome 8.41M 13.46M 43.91M 76.94M
Capital Expenditures -1.42M -12M -11.95M -23.57M

Income Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Research Development 52.97M 81.05M 124.74M 198.65M
Income Before Tax -54.45M 68.15M -84.55M -140.85M
Net Income -54.45M 67.97M -84.55M -140.85M
Selling General Administrative 19.11M 26.56M 56.41M 88.67M
Gross Profit 16.14M 168.8M 87.99M 138.29M
Ebit -55.94M 61.19M -93.16M -149.04M
Operating Income -55.94M 61.19M -93.16M -149.04M
Interest Expense
Income Tax Expense 2.4k 174k 2k 2k
Total Revenue 16.14M 168.8M 87.99M 138.29M
Cost Of Revenue
Total Other Income ExpenseNet 1.49M 6.96M 8.61M 8.19M
Net Income From Continuing Ops -54.45M 67.97M -84.55M -140.85M
Net Income Applicable To Common Shares -54.45M 67.97M -84.55M -140.85M

Balance Sheet Statement 2018-09-30 2019-09-30 2020-09-30 2021-09-30
Total Liabilities 16.37M 105.81M 60.73M 301.33M
Total Stockholder Equity 95.8M 244.59M 461.78M 408.82M
Other Current Liabilities 354.34k 77.96M 19.31M 114.16M
Total Assets 111.61M 349.85M 522.5M 710.15M
Common Stock 180.88k 187.88k 195k 197k
Other Current Assets 640.12k 2.56M 1.78M 2.19M
Retained Earnings -487.27M -419.29M -503.84M -644.69M
Treasury Stock -21.56k -391.62k 18k -69k
Cash 30.13M 221.8M 143.58M 184.43M
Total Current Liabilities 12.36M 97.07M 40.68M 146.54M
Other Stockholder Equity -21.56k -391.62k 18k -69k
Property, Plant, and Equipment 13.94M 23.21M 47.02M 66.02M
Total Current Assets 78.77M 265.25M 322.37M 384.6M
Net Tangible Assets 77.03M 227.53M 446.42M 395.16M
Net Receivables 327.38k 661.36k 846k 10.26M
Accounts Payable 2.81M 7.65M 6.83M 9.46M


Insider Transactions

Here are the insider transactions of stock shares related to Arrowhead Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
SAN MARTIN JAVIER M.D.Sale at price 29.98 - 30.62 per share.D2022-11-21Officer19.5k
ANZALONE CHRISTOPHER RICHARDConversion of Exercise of derivative security at price 30.77 - 31.21 per share.D2022-09-27Chief Executive Officer40.62k
ANZALONE CHRISTOPHER RICHARDConversion of Exercise of derivative security at price 14.54 per share.D2022-07-07Chief Executive Officer2.5k
MYSZKOWSKI KENNETH ALLENStock Gift at price 0.00 per share.D2022-06-15Chief Financial Officer96.68k
ANZALONE CHRISTOPHER RICHARDSale at price 50.51 - 53.11 per share.D2022-02-11Chief Executive Officer146.39k
ANZALONE CHRISTOPHER RICHARDConversion of Exercise of derivative security at price 5.19 per share.D2022-02-11Chief Executive Officer146.39k
OLUKOTUN ADEOYE YStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
GIVEN DOUGLASS BRUCEStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
PERRY MICHAEL SStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
ANZALONE CHRISTOPHER RICHARDConversion of Exercise of derivative security at price 5.19 per share.D2022-01-07Chief Executive Officer11.81k
FERRARI MAUROStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
WADDILL WILLIAM DStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
DE BACKER MARIANNEStock Award(Grant) at price 0.00 per share.D2022-01-07Director6.4k
MYSZKOWSKI KENNETH ALLENSale at price 60.50 - 63.95 per share.D2022-01-05Chief Financial Officer40k
O'BRIEN PATRICK CSale at price 60.49 - 64.35 per share.D2022-01-05General Counsel32.5k
HAMILTON JAMES CSale at price 60.51 - 69.38 per share.D2022-01-05Senior Vice President25.62k
OLUKOTUN ADEOYE YSale at price 64.26 - 66.25 per share.D2022-01-03Director4.05k
PERRY MICHAEL SSale at price 64.30 - 66.25 per share.D2022-01-03Director4.5k
WADDILL WILLIAM DSale at price 64.23 - 66.25 per share.D2022-01-03Director4.5k
DE BACKER MARIANNESale at price 64.25 - 66.25 per share.D2022-01-03Director4.5k
ANZALONE CHRISTOPHER RICHARDStock Award(Grant) at price 0.00 per share.D2021-12-31Chief Executive Officer800k
MYSZKOWSKI KENNETH ALLENStock Award(Grant) at price 0.00 per share.D2021-12-31Chief Financial Officer60k
O'BRIEN PATRICK CStock Award(Grant) at price 0.00 per share.D2021-12-31General Counsel60k
O'BRIEN PATRICK CConversion of Exercise of derivative security at price 6.15 per share.D2021-12-31General Counsel28k
HAMILTON JAMES CStock Award(Grant) at price 0.00 per share.D2021-12-31Senior Vice President55k
GIVEN DOUGLASS BRUCEPurchase at price 66.37 per share.D2021-12-28Director655
GIVEN DOUGLASS BRUCEStock Gift at price 0.00 per share.D2021-12-28Director655
FERRARI MAUROSale at price 66.82 per share.D2021-12-28Director3.4k
ANZALONE CHRISTOPHER RICHARDConversion of Exercise of derivative security at price 5.19 per share.D2021-12-23Chief Executive Officer11.81k
ANZALONE CHRISTOPHER RICHARDSale at price 66.28 - 70.19 per share.D2021-12-15Chief Executive Officer60k
SAN MARTIN JAVIER M.D.Sale at price 69.01 - 70.99 per share.D2021-11-19Officer19.5k
ANZALONE CHRISTOPHER RICHARDSale at price 65.57 - 66.23 per share.D2021-10-22Chief Executive Officer65k
OLUKOTUN ADEOYE YSale at price 63.76 per share.D2021-09-13Director5k
GIVEN DOUGLASS BRUCESale at price 65.24 per share.D2021-09-09Director5k
DE BACKER MARIANNESale at price 89.85 per share.D2021-06-24Director5k
GIVEN DOUGLASS BRUCESale at price 89.21 per share.D2021-06-22Director4.5k
HASSARD JAMESSale at price 89.22 per share.D2021-06-22Officer3.62k
GIVEN DOUGLASS BRUCESale at price 88.73 per share.I2021-02-22Director1.12k
O'BRIEN PATRICK CSale at price 86.72 - 89.66 per share.D2021-02-08General Counsel90k
O'BRIEN PATRICK CConversion of Exercise of derivative security at price 5.22 per share.D2021-02-08General Counsel90k
GIVEN DOUGLASS BRUCESale at price 83.28 per share.I2021-01-15Director3k
HAMILTON JAMES CSale at price 80.97 - 81.82 per share.D2021-01-14Senior Vice President10k
MYSZKOWSKI KENNETH ALLENSale at price 81.00 - 81.02 per share.D2021-01-12Chief Financial Officer13.04k
HASSARD JAMESSale at price 75.00 per share.D2021-01-07Officer15.62k
MYSZKOWSKI KENNETH ALLENSale at price 70.75 - 72.63 per share.D2021-01-06Chief Financial Officer30.62k
O'BRIEN PATRICK CSale at price 70.78 - 72.67 per share.D2021-01-06General Counsel25k
HAMILTON JAMES CSale at price 70.89 - 73.93 per share.D2021-01-06Senior Vice President38.75k
GIVEN DOUGLASS BRUCESale at price 76.08 per share.D2021-01-04Director4k
PERRY MICHAEL SSale at price 76.09 per share.D2021-01-04Director4k
WADDILL WILLIAM DSale at price 76.08 per share.D2021-01-04Director3.75k
OLUKOTUN ADEOYE YStock Award(Grant) at price 0.00 per share.D2021-01-01Director9k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Arrowhead Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Arrowhead Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Arrowhead Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Arrowhead Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Arrowhead Pharmaceuticals Inc:

Arrowhead Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 179.52% on the backtest period.

Performance at glance

Performance

179.52 %

Latent gain

3110.88 $

Invested capital

1732.92 $

Annualized return

43.79 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Arrowhead Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Arrowhead Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Arrowhead Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Arrowhead Pharmaceuticals Inc:

Arrowhead Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 394.32% of return on Arrowhead Pharmaceuticals Inc. That represents 18933.14$ of latent gain with 4801.48$ of employed capital.
  • The second momentum investment strategy would give 247.54% of return on Arrowhead Pharmaceuticals Inc. That represents 5577.6$ of latent gain with 2253.21$ of employed capital.
Performance at glance (1Q Momentum)

Performance

394.32 %

Latent gain

18933.14 $

Invested capital

4801.48 $

Annualized return

12.83 %
Performance at glance (2Q Momentum)

Performance

247.54 %

Latent gain

5577.6 $

Invested capital

2253.21 $

Annualized return

68.38 %

Momentum equity curve on Arrowhead Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Arrowhead Pharmaceuticals Inc:

Arrowhead Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Arrowhead Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Arrowhead Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Arrowhead Pharmaceuticals Inc since the beginning:

Arrowhead Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Arrowhead Pharmaceuticals Inc

Buy the dip entry openings on Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

The performance achieved by the robo-advisor on Arrowhead Pharmaceuticals Inc is 26.94%. That represents 205.6$ of latent gain with 763.16$ of employed capital. The following chart shows Arrowhead Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Arrowhead Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

26.94 %

Latent gain

205.6 $

Invested capital

763.16 $

Annualized return

12.83 %

Equity curve of the strategy applied to Arrowhead Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Arrowhead Pharmaceuticals Inc:

Arrowhead Pharmaceuticals Inc

Note: the dividends potentially given by Arrowhead Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Arrowhead Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Arrowhead Pharmaceuticals Inc:

Arrowhead Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Arrowhead Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Arrowhead Pharmaceuticals Inc.

Equity curve comparison on Arrowhead Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Arrowhead Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc investment comparison

Performance comparison on Arrowhead Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 179.52% 3110.88$ 1732.92$ 43.79%
Momentum 1 quarter 394.32% 18933.14$ 4801.48$ 102.16%
Momentum 2 quarters 247.54% 5577.6$ 2253.21$ 68.38%
Non-directional 26.94% 205.6$ 763.16$ 12.83%
Annualized return comparison

Automatic investment

43.79 %

Momentum 1Q

68.38 %

Momentum 2Q

68.38 %

Non-directional

12.83 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Arrowhead Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Arrowhead Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • Arrowhead Pharmaceuticals Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • HING LEE (HK)

  • Note: The algorithm computes the probability of correlation between Arrowhead Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Arrowhead Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Arrowhead Pharmaceuticals Inc
    Country United States
    City Pasadena
    Address 177 East Colorado Boulevard
    Phone 626 304 3400
    Website arrowheadpharma.com
    FullTime employees 329
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ARWR
    Market www.nasdaq.com

    Arrowhead Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown